Immutep LtdASX: IMM

Upcoming Poster Presentations at CTOS and ESMO IO 2026

Nov 4, 2026 at 4:24 PM EST · Issued by Immutep Ltd via ASX

Filed with ASX · Nov 4, 2026 at 4:24 PM EST · 2 pages · English

On 6ix: 6ix.com/news/upcoming-poster-presentations-at-ctos-and-esmo-io-2026-1

Release

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 SYDNEY, AUSTRALIA – November 5, 2026 — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer...

Immutep Ltd on 6ix

Story so far

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025Nov 13, 2025
EFTISARC-NEO Phase II results presented at CTOS 2025Nov 13, 2025
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025Sep 8, 2025

Earlier from Immutep

Immutep Quarterly Activities Report and Appendix 4COct 28
Immutep Receives A$2.16 million French R&D Tax IncentiveOct 27
Notice of Annual General Meeting/Proxy FormOct 26
Appendix 4G and Corporate Governance StatementOct 26
Annual Report to shareholdersOct 26

All Immutep news releases

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep